The heparin-binding site of antithrombin is crucial for antiangiogenic activity

Blood

Volumn 106, Issue 5, 2005, Pages 1621-1628

  Zhang, Weiqing ^a   Swanson, Richard ^a   Izaguirre, Gonzalo ^a   Xiong, Yan ^a   Lau, Lester F ^a   Olson, Steven T ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; ASPARAGINE; BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; HEPARIN; LYSINE; PENTASACCHARIDE; PERLECAN; SERINE PROTEINASE INHIBITOR;

ANTIANGIOGENIC ACTIVITY; ARTICLE; BINDING AFFINITY; CAPILLARY PROLIFERATION; CELL MIGRATION; CELL PROLIFERATION; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG BINDING SITE; DRUG PROTEIN BINDING; ENDOTHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN MODIFICATION; UMBILICAL VEIN;

EID: 23944454401     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2005-02-0547     Document Type: Article

References (51)

1. Björk I, Olson ST. Antithrombin, a bloody important serpin. In: Church FC, Cunningham DD, Ginsburg D, Hoffman M, Stone SR, Tollefsen DM, eds. Chemistry and Biology of Serpins. New York, NY: Plenum Press; 1997:17-33.
2. Van Boven HH, Lane DA. Antithrombin and its inherited deficiency states. Semin Hematol. 1997;34:188-204.
3. Ishiguro K, Kojima T, Kadomatsu K, et al. Complete antithrombin deficiency in mice results in embryonic lethality. J Clin Invest. 2000;106:873-878.
4. Bedsted T, Swanson R, Chuang Y-J, Bock PE, Björk I, Olson ST. Heparin and calcium ions dramatically enhance antithrombin reactivity with factor IXa by generating new interaction exosites. Biochemistry. 2003;42:8143-8152.
5. Gettins PGW. Serpin structure, mechanism, and function. Chem Rev. 2002;102:4751-4803.
6. Marcum JA, Atha DH, Fritze LMS, Nawroth PP, Stern DM, Rosenberg RD. Cloned bovine aortic endothelial cells synthesize anticoagulantly active heparan sulfate proteoglycan. J Biol Chem. 1986;261:7507-7517.
7. Olson ST, Björk I, Sheffer R, Craig PA, Shore JD, Choay J. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions: resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem. 1992;267:12528-12538.
8. Jin L, Abrahams JP, Skinner R, Petitou M, Pike RN, Carrell RW. The anticoagulant activation of antithrombin by heparin. Proc Natl Acad Sci U S A. 1997;94:14683-14688.
9. Oelschläger C, Römisch J, Staubitz A, et al. Antithrombin III inhibits nuclear factor kB activation in human monocytes and vascular endothelial cells. Blood. 2002;99:4015-4020.
10. Geiben-Lynn R, Brown N, Walker BD, Luster AD. Purification of a modified form of bovine antithrombin III as an HIV-1 CD8+ T-cell antiviral factor. J Biol Chem. 2002;277:42352-42357.
11. O'Reilly MS, Pine-Shepherd S, Lane WS, Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science. 1999;285:1926-1928.
12. Larsson H, Sjoblom T, Dixelius J, et al. Antiangiogenic effects of latent antithrombin through perturbed cell-matrix interactions and apoptosis of endothelial cells. Cancer Res. 2000;60:6723-6729.
13. Prox D, Becker C, Pirie-Shepherd SR, Celik I, Folkman J, Kisker O. Treatment of human pancreatic cancer in mice with angiogenic inhibitors. World J Surg. 2003;68:47-54.
14. Mourey L, Samama JP, Delarue M, Petitou M, Choay J, Moras D. Crystal structure of cleaved bovine antithrombin III at 3.2 A resolution. J Mol Biol. 1993;232:223-241.
15. Skinner R, Abrahams J-P, Whisstock JC, Lesk AM, Carrell RW, Wardell MR. The 2.6 A structure of antithrombin indicates a conformational change at the heparin binding site. J Mol Biol. 1997;266:601-609.
16. Björk I, Fish WW. Production in vitro and properties of a modified form of bovine antithrombin, cleaved at the active site by thrombin. J Biol Chem. 1982;257:9487-9493.
17. Wardell MR, Chang WSW, Bruce D, Skinner R, Lesk AM, Carrell RW. Preparative induction and characterization of L-antithrombin: a structural homologue of latent plasminogen activator inhibitor-1. Biochemistry. 1997;36:13133-13142.
18. Marciniak E. Thrombin-induced proteolysis of human antithrombin III: an outstanding contribution of heparin. Br J Haematol. 1981;48:325-336.
19. Zhou A, Huntington JA, Carrell RW. Formation of the antithrombin heterodimer in vivo and the onset of thrombosis. Blood. 1999;94:3388-3396.
20. Zhang W, Chuang YJ, Swanson R, et al. Antiangiogenic antithrombin down-regulates the expression of the proangiogenic heparan sulfate proteoglycan, perlecan, in endothelial cells. Blood. 2004;103:1185-1191.
21. Scheiden-Weiss S, Desai UR, Bock SC, Gettins PGW, Olson ST, Björk I. The importance of lysine 125 for heparin binding and activation of antithrombin. Biochemistry. 2002;41:4779-4788.
22. Arocas V, Bock SC, Raja SM, Olson ST, Björk I. Lysine 114 of antithrombin is of crucial importance for the affinity and kinetics of heparin pentasaccharide binding. J Biol Chem. 2001;276:43809-43817.
23. Chuang, YJ, Swanson R, Raja SM, Bock SC, Olson ST. The antithrombin P1 residue is important for target proteinase specificity but not for heparin activation of the serpin: characterization of P1 antithrombin variants with altered proteinase specificity but normal heparin activation. Biochemistry. 2001;40:6670-6679.
24. Turk B, Brieditis I, BockSC, Olson ST, Björk I. The oligosaccharide side chain on Asn-135 of β-antithrombin, absent in α-antithrombin, decreases the heparin affinity of the inhibitor by affecting the heparin-induced conformational change. Biochemistry. 1997;36:6682-6691.
25. Björk I, Ylinenjärvi K, Olson ST, Hermentin P, Conradt HS, Zettlmeissl G. Decreased affinity of recombinant antithrombin for heparin due to increased glycosylation. Biochem J. 1992;286:793-800.
26. Garone L, Edmunds T, Hanson E, et al. Antithrombin-heparin affinity reduced by fucosylation of carbohydrate at asparagine 155. Biochemistry. 1996;35:8881-8889.
27. Olson ST, Francis-Chmura AM, Swanson R, Björk I, Zettlmeissl G. Effect of individual carbohydrate chains of recombinant antithrombin on heparin affinity and on the generation of glycoforms differing in heparin affinity. Arch Biochem Biophys. 1997;341:212-221.
28. Olson ST, Björk I, Shore JD. Kinetic characterization of heparin-catalyzed and uncatalyzed inhibition of blood coagulation proteinases by antithrombin. Methods Enzymol. 1993;222:525-560.
29. Herbert JM, Hèrault JP, Bernat A, et al. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood. 1998;91:4197-4205.
30. van Boeckel CAA, Petitou M. The unique antithrombin III binding domain of heparin: a lead to new synthetic antithrombotics. Angew Chem Int Ed Engl. 1993;32:1671-1690.
31. Meagher JL, Olson ST, Gettins PGW. Critical role of the linker region between helix D and strand 2A in heparin activation of antithrombin. J Biol Chem. 2000;275:2698-2704.
32. Santos MF, McCormack SA, Quo Z, et al. Rho proteins play a critical role in cell migration during the early phase of mucosal restitution. J Clin Invest. 1997;100:216-225.
33. Yokote K, Mori S, Siegbahn A, et al. Structural determinants in the platelet-derived growth factor alpha-receptor implicated in modulation of chemotaxis. J Biol Chem. 1996;271:5101-5111.
34. Grant DS, Lelkes PI, Fukuda K, Kleinman HK. Intracellular mechanisms involved in basement membrane induced blood vessel differentiation in vitro. In Vitro Cell Dev Biol. 1991;27A:327-336.
35. Iozzo RV, Pillarisetti J, Sharma B, et al. Structural and functional characterization of the human perlecan gene promoter: transcriptional activation of transforming growth factor-β via a nuclear factor-1 binding element. J Biol Chem. 1997;272:5219-5228.
36. Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 1983;11:1475-1489.
37. Skinner R, Chang WSW, Jin L, et al. Implications for function and therapy of a 2.9 Å structure of binary-complexed antithrombin. J Mol Biol. 1998;283:9-14.
38. de Agostini AI, Watkins SC, Slayter HS, Youssoufian H, Rosenberg RD. Localization of anticoagulantly active heparan sulfate proteoglycans in vascular endothelium: antithrombin binding on cultured endothelial cells and perfused rat aorta. J Cell Biol. 1990;111:1293-1304.
39. Mertens G, Cassiman JJ, Van den Berghe H, Vermylen J, David G. Cell surface heparan sulfate proteoglycans from human vascular endothelial cells: core protein characterization and antithrombin III binding properties. J Biol Chem. 1992;267:20435-20443.
40. Carmeliet P. Angiogenesis in health and disease. Nature Med. 2003;9:653-660.
41. Spivak-Kroizman T, Lemmon MA, Dikic I, et al. Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation and cell proliferation. Cell. 1994;79:1015-1024.
42. Klint P, Claesson-Welsh L. Signal transduction by fibroblast growth receptors. Front Biosci. 2000;275:24653-24660.
43. Lundin L, Larsson H, Kreuger J, et al. Selectively desulfated heparin inhibits fibroblast growth factor-induced mitogenicity and angiogenesis. J Biol Chem. 2000;275:24653-24660.
44. Aviezer D, Hecht D, Safran M, Eisinger M, David G, Yayon A. Perlecan, basai lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis and angiogenesis. Cell. 1994;79:1005-1013.
45. Sharma B, Handler M, Eichstetter I, Whitelock JM, Nugent MA, Iozzo RV. Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo. J Clin Invest. 1998;102:1599-1608.
46. Sasaki T, Larsson H, Kreuger J, et al. Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin. EMBO J. 1999;18:6240-6248.
47. Miao RQ, Agata J, Chao L, Chao J. Kallistatin is a new inhibitor of angiogenesis and tumor growth. Blood. 2002;100:3245-3252.
48. Kreuger J, Matsumoto T, Vanwildemeersch M, et al. Role of heparan sulfate domain organization in endostatin inhibition of endothelial cell function. EMBO J. 2002;21:6303-6311.
49. Streusand VJ, Björk I, Gettins PGW, Petitou M, Olson ST. Mechanism of acceleration of antithrombin-proteinase reactions by low affinity heparin: role of the antithrombin binding pentasaccharide in heparin rate enhancement. J Biol Chem. 1995;270:9043-9051.
50. Plotnikov AN, Schlessinger J, Hubbard SR, Mohammadi M. Structural basis for FGF receptor dimerization and activation. Cell. 1999;98:641-650.
51. Abdollani A, Hahnfeldt P, Maercker C, et al. Endostatin's antiangiogenic signaling network. Mol Cell. 2004;13:649-663.